STAT Plus: Cymabay’s NASH drug ambitions dealt serious setback with negative study results
ADOBE
In the Phase 2 study, three oral doses of the company's lead drug, called seladelpar, all performed worse than a placebo.
Clinical and Molecular Allergy
Hace 4 horas
No hay comentarios:
Publicar un comentario